Tranexamic acid

Escape to the Tropics with Eminence Organics' New Tropical Superfood Collection

Retrieved on: 
Wednesday, March 1, 2023
Tranexamic acid, Collection, Tonique Williams-Darling, Skin, PHA, Agonis flexuosa, Spirulina, Cosmetics

NEW YORK, March 1, 2023 /PRNewswire/ -- Award-winning professional skin care brand Eminence Organic Skin Care is excited to announce the launch of its Tropical Superfood Collection .

Key Points: 
  • NEW YORK, March 1, 2023 /PRNewswire/ -- Award-winning professional skin care brand Eminence Organic Skin Care is excited to announce the launch of its Tropical Superfood Collection .
  • Harnessing the power of tropical superfoods with energizing formulas, this collection pairs replenishing PHA, which gently exfoliates, with vitamin-rich botanicals to boost your natural glow.
  • The innovative textures and tropical scents treat your skin to a unique, glow-enhancing experience.
  • Superfood Booster-Powder ($60) Packed with superfoods, this ultra-fine powder targets uneven skin tone and reduces the appearance of dark spots.

SkinMedica® Launches Even & Correct

Retrieved on: 
Tuesday, January 17, 2023
Dark, Cream, Melasma, Hyperpigmentation, Face, PIH, LTN, Dermatology, Collection, Senior, NYSE, Phytochemical, ABBV, Tranexamic acid, Titanium metallic discoloration, Patient, Metabolic pathway, John Foster Dulles, Physician, Science, Serum, AbbVie, MSRP, Skin discoloration, Cosmetics, Nicotinamide, Correctness

IRVINE, Calif., Jan. 17, 2023 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the launch of the long-awaited SkinMedica® Even & Correct Collection. Clinically proven and formulated to deliver targeted results, these three products work separately and together to even skin tone and reduce the appearance of hyperpigmentation and dark spots on the face: Advanced Brightening Treatment, Dark Spot Cream, and Brightening Treatment Pads.

Key Points: 
  • The SkinMedica® Even & Correct products are hydroquinone-free, well tolerated, and effective on all skin types and for multiple ethnicities.
  • SkinMedica® Even & Correct Dark Spot Cream: A heavy-duty, targeted, fast-acting spot treatment booster that minimizes the look of dark spots.
  • SkinMedica® Even & Correct Brightening Treatment Pads: Alcohol-free brightening pads exfoliate and help reduce the appearance of dullness and uneven tone and texture.
  • SkinMedica® Even & Correct Advanced Brightening Treatment ($178 MSRP), SkinMedica® Even & Correct Dark Spot Cream ($88 MSRP), and SkinMedica® Even & Correct Brightening Treatment Pads ($60 MSRP) are available for purchase at SkinMedica.com , and through a network of licensed physicians and medically supervised spas.

The Worldwide Anticoagulant Reversal Drugs Industry is Expected to Reach $1.6 Billion by 2027 - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 13, 2022
Health, Pharmaceutical, Emotion, Product distribution, Tranexamic acid, Ansoff Matrix, Risk, Observation, Growth, SWOT, CAGR, Porter's five forces analysis, Atrial fibrillation, Investment, Hospital, Geography, Product, Industry, Market development, Prevalence, Competitive analysis, Pharmacy, COVID-19, USD, Intracranial hemorrhage, Pharmaceutical industry, Marketing, Retail, Fine chemical, Risk management, Distribution

The Global Anticoagulant Reversal Drugs Market is estimated to be worth USD 807.2 million in 2022, and is expected to reach USD 1,616.52 million by 2027, growing at a CAGR of 14.9%.

Key Points: 
  • The Global Anticoagulant Reversal Drugs Market is estimated to be worth USD 807.2 million in 2022, and is expected to reach USD 1,616.52 million by 2027, growing at a CAGR of 14.9%.
  • The Global Anticoagulant Reversal Drugs Market is segmented based on Products, Distribution, and Geography.
  • The report presents a detailed Ansoff matrix analysis for the Global Anticoagulant Reversal Drugs Market.
  • The report offers a comprehensive evaluation of the Global Anticoagulant Reversal Drugs Market.

Master Skincare Formulator Develops New Method to Remove Appearance of Fine Lines Without Cosmetic Surgery

Retrieved on: 
Tuesday, September 27, 2022
Glass, Elastin, Oxygen, Ageing, NMF, Skin, Hyaluronic acid, Face, Best, MSRP, De l'amour le mieux, Nutrient, Physician, Serum, IOI, Cell, Tranexamic acid, Doubly ionized oxygen, Collagen, Multimedia, Peptide, Phosphorus, Cosmetics

PASADENA, Calif., Sept 27, 2022 /PRNewswire/ -- Ready to give your face a lift without the face lift? The trusted beauty experts at Le Mieux Skincare say now you can with an innovative skincare system known as the OMG Let's Glow Trio. Highlighting its new Ionized Oxygen Infuser™ (IOI) along with the brand's best-selling Oh My Glow™ Activator and Oh My Glow™ Serum, the OMG Let's Glow Trio by Le Mieux is sure to have consumers exclaiming "OMG!" when fine lines seem to disappear after just one use.

Key Points: 
  • The trusted beauty experts at Le Mieux Skincare say now you can with an innovative skincare system known as the OMG Let's Glow Trio .
  • when fine lines seem to disappear after just one use.
  • Beauty serum authority Le Mieux Skincare develops OMG Let's Glow Trio to plump skin and remove appearance of fine lines.
  • "The OMG Let's Glow Trio offers a smarter way to apply serum like a pro and remove visible signs of aging," said Le Mieux founder and master skincare formulator Janel Luu.

Hyloris Pharmaceuticals Reports 2022 Half-Year Results and Provides Corporate Update

Retrieved on: 
Thursday, September 1, 2022
Quality, Patient, NDA, IC/BPS, Pharmacokinetics, Program, Pain, VWAP, IV, Extraction (chemistry), ACS, Exercise, Tranexamic acid, Roemheld syndrome, Physician, EUR, Review, Annual general meeting, Milrinone, Company, FDA, Population, Information, Group, CRL, Bleeding, HF, Risk, Marketing, Woman, Endpoint security, Atrial fibrillation, LVAD, Euronext, Medical device, Pharmaceutical industry, Security (finance), Sotalol

Hyloris will generate additional data on extractables and leachables from the packaging components to respond to the FDAs information request.

Key Points: 
  • Hyloris will generate additional data on extractables and leachables from the packaging components to respond to the FDAs information request.
  • Hyloris and its partnerhave completed the clinical phase of the study to assess the pharmacokinetics of this product candidate.
  • Hyloris has contracted with a manufacturing organization to produce registration batches in preparation for an NDA submission to the FDA.
  • On 22 June 2022 Hyloris increased its capital and share premium with 2.8 million through the exercise of 1.2 million outstanding transactions warrants.

Palisade Bio Announces First Patient Enrolled and Dosed in Pivotal Phase 3 Study Evaluating LB1148 for Postoperative Return of Bowel Function

Retrieved on: 
Wednesday, August 17, 2022
Gastrointestinal tract, Principal, Risk, NDA, Forward-looking statement, Ohio State University, Trial of the century, GLOBE, Disease, Standard of care, Private Securities Litigation Reform Act, Laparotomy, Incidence, Ohio State University Wexner Medical Center, Research, Communication, Health, Patient, Company, Food, Therapy, Safety, Biology, Tranexamic acid, Science, Nasdaq, Adult, Pharmaceutical industry, Palisade

The design of this Phase 3 study mirrors that of our positive Phase 2 study where LB1148 demonstrated a statistically significant improvement in the time of return of bowel function.

Key Points: 
  • The design of this Phase 3 study mirrors that of our positive Phase 2 study where LB1148 demonstrated a statistically significant improvement in the time of return of bowel function.
  • LB1148 represents a promising opportunity to establish the standard of care for accelerating the postoperative return of bowel function.
  • The clinical study will utilize the same dosing of LB1148 used in the companys completed Phase 2 study in which LB1148 demonstrated a 1.1-day improvement in return of bowel function.
  • LB1148 is currently being evaluated in a Phase 3 clinical study for accelerating the return of postoperative bowel function and in a Phase 2 study for the prevention of post-surgical abdominal adhesions.

Palisade Bio Launches New Corporate Website and Reiterates Commitment to Develop Therapeutics that Protect Intestinal Barrier Health

Retrieved on: 
Monday, August 1, 2022
GLOBE, Tranexamic acid, Twitter, Health, Forward-looking statement, Research, Incidence, Private Securities Litigation Reform Act, Disease, Company, Gastrointestinal tract, Patient, LinkedIn, Science, Biology, Therapy, Communication, Investor, Pharmaceutical industry, Medical imaging, Palisade, Facebook

CARLSBAD, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the launch of its new corporate website, palisadebio.com and reiterates its commitment to all stakeholders by developing therapeutics that protect intestinal barrier health.

Key Points: 
  • CARLSBAD, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the launch of its new corporate website, palisadebio.com and reiterates its commitment to all stakeholders by developing therapeutics that protect intestinal barrier health.
  • I am excited for this next phase of evolution for Palisade Bio and the future of this impactful company.
  • The therapy is being developed for administration prior to surgeries that disrupt the intestinal epithelial barrier.
  • Palisade Bio is a late-stage biopharmaceutical company focused on developing therapeutics that protect the integrity of the intestinal barrier.

Palisade Bio Announces First Patient Screened in Phase 3 Study Evaluating LB1148 for Postoperative Return of Bowel Function

Retrieved on: 
Wednesday, July 27, 2022
Food, GLOBE, Tranexamic acid, Trial of the century, Forward-looking statement, Private Securities Litigation Reform Act, Risk, Adult, Safety, Gastrointestinal tract, Patient, Standard of care, Nasdaq, Laparotomy, Length of stay, Communication, Dentistry, Pharmaceutical industry, Palisade, ICU

The operational execution of our Phase 3 clinical development program for LB1148 remains our number one priority.

Key Points: 
  • The operational execution of our Phase 3 clinical development program for LB1148 remains our number one priority.
  • We believe that LB1148 has the opportunity to potentially establish the standard of care for millions of patients undergoing abdominal surgeries each year.
  • The clinical study will utilize the same dosing of LB1148 used in the companys completed Phase 2 study in which LB1148 demonstrated a 1.1-day improvement in return of bowel function.
  • Palisade Bios innovative Phase 3 lead asset LB1148, is a protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery.

Hyloris Reports Positive Phase 1 Data for HY-004, a proprietary Tranexamic Acid Oral Mouth Rinse for bleeding related to dental procedures

Retrieved on: 
Wednesday, July 20, 2022
IV, Medicaid, Extraction (chemistry), Oral and maxillofacial surgery, Coagulopathy, Tranexamic acid, Industry, Bleeding, Commercial, Risk, Safety, Euronext, Atrial fibrillation, Company, Patient, LinkedIn, Coagulation, CEST, Medicare, Haemophilia, Dentistry, Birth control, Pharmaceutical industry

Hyloris Reports Positive Phase 1 Data for HY-004, a proprietary Tranexamic Acid Oral Mouth Rinse for bleeding related to dental procedures

Key Points: 
  • Hyloris Reports Positive Phase 1 Data for HY-004, a proprietary Tranexamic Acid Oral Mouth Rinse for bleeding related to dental procedures
    Lige, Belgium - 20 July 2022 - 07:00 AM CEST - Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announced positive results from a Phase 1 study of HY-004, an antifibrinolytic agent, tranexamic acid, as an oral mouth rinse proprietary formulation (Tranexamic Acid Oral Solution, 5%) in healthy patients following tooth extraction.
  • Hyloris also plans to investigate its use for broader related indications in patients undergoing oral surgical procedures with or without bleeding disorders that would benefit from a locally-actingantifibrinolytic agent.
  • Having a tranexamic acid oral rinse could serve the needs of more than 8 million12 US people taking a blood thinner medication.
  • Hyloris HY-004 is a proprietary reformulated oral rinse developed for use in minor surgical procedures with complications/bleedings.

Get Even with Uneven Skin, PCA SKIN® Introduces New Pigment Gel® Pro

Retrieved on: 
Tuesday, July 5, 2022
Dark, SKIN, Greg Camp, Science, Patient, Nicotinamide, Research, Skin discoloration, BBL, Trial of the century, FAAD, Lactic acid, R, Female, Industry, Face, LLC, Colgate-Palmolive, Intensity, 4-Butylresorcinol, Tranexamic acid, Skin care, Health, Skin, PCA, Physician, Multimedia, CP, Light, Cosmetics, Silviculture, Hexylresorcinol, MD

SCOTTSDALE, Ariz., July 5, 2022 /PRNewswire/ -- PCA SKIN®, a leader in professional peel treatments and transformative daily skincare products, introduces their latest advanced corrective, Pigment Gel® Pro; a clinically-proven formula designed to target and combat stubborn discoloration across all skin types and tones.

Key Points: 
  • PCA SKINPigment Gel Pro is powered by this proprietary technology containing efficacious levels of advanced ingredients to deliver a visibly dramatic reduction in the appearance of stubborn discoloration.
  • We are confident we will achieve both missions with the launch of the new Pigment Gel Pro."
  • PCA SKIN continues to be a trusted innovator in the development of highly effective professional treatments and daily skin care products.
  • PCA SKINtreatments and products are available through licensed skin health professionals that have been trained and certified by PCA SKIN in their use.